|
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
|
Jan 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
|
Oct 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
|
Jul 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Expression of nucleoside metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
|
Nov 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria
|
Jan 2021
|
Leukemia
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Diagnostic algorithm for lower-risk myelodysplastic syndromes
|
Jun 2018
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS
|
Jun 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
|
Nov 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
|
Feb 2012
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
